Compare Liberty Global Ltd Class C (LBTYK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Viatris Inc — how do they compare? Liberty Global Ltd Class C trades at $8.52 (market cap $3.06B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 6.5× Liberty Global Ltd Class C's market cap, and Viatris Inc pays a 2.75% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Viatris Inc for 57 Days on average.
| LBTYK | VTRS | |
|---|---|---|
Market Cap | $3.06B | $20.03B |
Volume | 2,508,956 | 14,109,977 |
Sector | Media | Health |
52-Week High | $12.67 | $18.27 |
52-Week Low | $8.75 | $9.74 |
Typical Hold Time | 21 Days | 57 Days |
Enterprise Value | $9.72B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.52, down 4.48% amid bearish technical signals. The stock shows mixed fundamentals with strong gross margins of 67.17% but significant net losses. Recent earnings have been volatile, with Q1 2026 beating expectations but Q2 missing. The company is progressing with strategic initiatives including the Ziggo Group spin-off planned for 2027 and an AI partnership with Sierra.
Despite current losses, analyst consensus remains bullish with a $12.67 price target, suggesting 49% upside. Key risks include execution of the Ziggo listing and sustained profitability challenges. The cash position and asset monetization provide downside support, while the planned 2027 value-unlock event represents the primary growth catalyst.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
